4,204 results match your criteria advanced hodgkin


Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.

Int J Hematol 2021 Sep 21. Epub 2021 Sep 21.

Medical Oncology Intercentre Unit, Regional and Virgen de La Victoria University Hospitals, IBIMA, Teatinos, s/n, C.P., 29010, Málaga, Spain.

Up to 25% of patients with classical Hodgkin lymphoma (cHL) and a negative interim PET/CT will progress. Unfortunately, there are few published studies on the predictive value of PET/CT performed after finishing treatment. The objective of our study was to assess the role of the final PET/CT (fPET/CT) in predicting progression in a retrospective series of patients treated in the last 10 years with a homogeneous protocol (ABVD + / - radiotherapy). Read More

View Article and Full-Text PDF
September 2021

Plasmablastic lymphoma: case report.

Rev Med Inst Mex Seguro Soc 2020 ;58(4):511-516

Instituto Mexicano del Seguro Social, Centro Médico Nacional La Raza, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Departamento de Medicina Interna. Ciudad de México, México.

IntroducciÓn: El linfoma plasmablástico es un linfoma no Hodgkin de alto grado. Se describe en pacientes con infección por el virus de la inmunodeficiencia humana (VIH), en receptores de trasplantes y en pacientes de edad avanzada. Se presenta en la cuarta década de la vida, siendo la cavidad oral el sitio más común de afección. Read More

View Article and Full-Text PDF
January 2020

Prognostic Indicators of Survival in Sinonasal Diffuse Large B-Cell Lymphoma: A National Cancer Database Analysis.

Laryngoscope 2021 Sep 20. Epub 2021 Sep 20.

Rush Sinus Program, Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, Illinois, U.S.A.

Objectives/hypothesis: This study offers an update on the epidemiologic and prognostic factors and treatment-specific outcomes in patients diagnosed with sinonasal diffuse large B-cell lymphoma (DLBCL).

Study Design: Retrospective cohort study.

Methods: National Cancer Database was queried from 2004 to 2016 for patients with sinonasal DLBCL. Read More

View Article and Full-Text PDF
September 2021

Non-Hodgkin Lymphoma: Examining Mycosis Fungoides and Sézary Syndrome in the Context of Oncology Nursing.

Clin J Oncol Nurs 2021 Oct;25(5):555-562

Billings Clinic.

Background: Mycosis fungoides and Sézary syndrome are the most common non-Hodgkin lymphomas that manifest primarily in the skin. Although early-stage disease has an excellent long-term survival rate, advanced disease carries a poor survival rate. Given the lengthy and complex clinical course, nurses are at the forefront of education and supportive care management for patients and caregivers. Read More

View Article and Full-Text PDF
October 2021

Progress and pitfalls with the use of image-guided personalised approaches in lymphoma.

Br J Radiol 2021 Sep 14:20210609. Epub 2021 Sep 14.

Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust, Manchester, UK.

The use of F-FDG PET CT has become an essential part of the management of patients with lymphoma. The last decade has seen unrivalled progress in research efforts to personalise treatment approaches using PET as a predictive imaging biomarker. Critical to this success has been the standardisation of PET methods and reporting, including the 5-point Deauville scale, which has enabled the delivery of robust clinical trial data to develop response-adapted treatment approaches. Read More

View Article and Full-Text PDF
September 2021

9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Br J Haematol 2021 Sep 14. Epub 2021 Sep 14.

Institute of Pathology, University of Würzburg, Würzburg, Germany.

High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed-Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24. Read More

View Article and Full-Text PDF
September 2021

Assessment and Management of Newly Diagnosed Classical Hodgkin Lymphoma: A Consensus Practice Statement from the Australasian Lymphoma Alliance.

Intern Med J 2021 Sep 9. Epub 2021 Sep 9.

Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.

The management of Hodgkin Lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment related morbidity is a constant source of concern, for physicians and patients alike. PET adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, whilst minimising toxicities. Read More

View Article and Full-Text PDF
September 2021

Spiking Neural Networks and Hippocampal Function: A Web-Accessible Survey of Simulations, Modeling Methods, and Underlying Theories.

Cogn Syst Res 2021 Dec 31;70:80-92. Epub 2021 Jul 31.

Department of Bioengineering, 4400 University Drive, George Mason University, Fairfax, Virginia, 22030 (USA).

Computational modeling has contributed to hippocampal research in a wide variety of ways and through a large diversity of approaches, reflecting the many advanced cognitive roles of this brain region. The intensively studied neuron type circuitry of the hippocampus is a particularly conducive substrate for spiking neural models. Here we present an online knowledge base of spiking neural network simulations of hippocampal functions. Read More

View Article and Full-Text PDF
December 2021

[Initial treatment strategy for classical Hodgkin lymphoma in adults].

Authors:
Shigeru Kusumoto

Rinsho Ketsueki 2021 ;62(8):1102-1111

Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences.

Four cycles of ABVD followed by 30 Gy IFRT (ISRT) is a standard regimen, as an initial treatment, for patients with early-stage classical Hodgkin lymphoma (cHL), whereas 2 cycles of ABVD followed by 20 Gy IFRT (ISRT) is an alternative regimen for those with favorable early-stage cHL. For patients with unfavorable early-stage cHL including bulky disease, local radiotherapy can be safely omitted if negative findings on interim PET are obtained after 2 cycles of escalated BEACOPP plus 2 cycles of ABVD. ABVD (6/8 cycles) or brentuximab vedotin (BV) with concurrent AVD (6 cycles) is a standard regimen for patients with advanced-stage cHL. Read More

View Article and Full-Text PDF
September 2021

Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s.

Eur J Cancer 2021 Sep 4;157:81-93. Epub 2021 Sep 4.

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. Electronic address:

Background: This is the first national study on trends in cancer survival and mortality for children and young adolescents in the Netherlands including unique information on stage at diagnosis.

Methods: All neoplasms in patients <18 years, diagnosed between 1990 and 2015 (N = 14,060), were derived from the Netherlands Cancer Registry. Cohort and period survival analyses were used to estimate observed survival (OS). Read More

View Article and Full-Text PDF
September 2021

Could Camrelizumab Plus Chemotherapy Improve Clinical Outcomes in Advanced Malignancy? A Systematic Review and Network Meta-Analysis.

Front Oncol 2021 9;11:700165. Epub 2021 Aug 9.

Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.

Purpose: Camrelizumab is a novel programmed cell death 1 (PD-1) inhibitor. To determine the efficacy and safety of the combination treatment of camrelizumab+chemotherapy and camrelizumab monotherapy, and determine which is the most suitable malignancy type to be treated with camrelizumab, we performed a systematic review and network meta-analysis.

Methods: We searched PubMed, Embase, and the Cochrane Library for published clinical trials from database inception until April 2021. Read More

View Article and Full-Text PDF

Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma.

Ups J Med Sci 2021 20;126. Epub 2021 Aug 20.

Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology; Uppsala University, Uppsala, Sweden.

Background: Thymidine kinase 1 (TK1) is an intracellular protein associated with DNA synthesis, expressed during the G1 phase and remained elevated through the M phase, with a potential as a biomarker for cell proliferation. In this study, we explore the possible use of TK1 in Hodgkin lymphoma (HL).

Methods: Serum concentrations of TK1 (S-TK1) were measured in 46 newly diagnosed HL patients using prospectively collected biobanked serum samples. Read More

View Article and Full-Text PDF

Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma.

Cancer Manag Res 2021 26;13:6731-6741. Epub 2021 Aug 26.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, 100142, People's Republic of China.

Background: In the present study, we have tried to understand how the level of risk and survival probability changes over time for patients with classical Hodgkin's lymphoma by employing conditional survival and annual hazard as dynamic estimates of prognosis and survival.

Methods: This retrospective study reviewed the clinical data of patients with newly diagnosed classical Hodgkin's lymphoma admitted to Peking University Cancer Hospital between January 1, 2008, and December 31, 2017. Conditional survival and annual hazard rate were defined as the survival probability and yearly event rate, respectively, assuming that patients have survived for a defined time. Read More

View Article and Full-Text PDF

The impact of cancer on the risk of death with a functioning graft of Italian kidney transplant recipients.

Am J Transplant 2021 Aug 31. Epub 2021 Aug 31.

Department of Epidemiology and Pre-Clinical Research, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy.

This study assessed the impact of cancer on the risk of death with a functioning graft of kidney transplant (KT) recipients, as compared to corresponding recipients without cancer. A matched cohort study was conducted using data from a cohort of 13 245 individuals who had undergone KT in 17 Italian centers (1997-2017). Cases were defined as subjects diagnosed with any cancer after KT. Read More

View Article and Full-Text PDF

Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study.

Eur J Cancer 2021 Aug 27. Epub 2021 Aug 27.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address:

Background: GLS-010 (zimberelimab) is a novel, fully human, anti-programmed death-1 monoclonal antibody that shows promising efficacy and safety in advanced solid tumors. This trial aimed to evaluate the efficacy and safety of GLS-010 (zimberelimab) in Chinese patients with relapsed or refractory classical Hodgkin lymphoma (r/r-cHL).

Methods: This phase II, single-arm, open-label, multicenter clinical trial was conducted at 24 centers in China and enrolled patients with r/r-cHL after two or more lines of therapy. Read More

View Article and Full-Text PDF

eBEACOPP or A-AVD in advanced Hodgkin lymphoma: (re)thinking the toxicities in the PET-driven strategies era.

Lancet Haematol 2021 Sep;8(9):e620

Service d'hématologie et thérapie cellulaire, Centre Hospitalier Universitaire de Bordeaux, 33600 Bordeaux, France.

View Article and Full-Text PDF
September 2021

Treatment results of modified BFM protocol in pediatric high-risk Burkitt lymphoma.

Turk J Pediatr 2021 ;63(4):639-647

Department of Pediatric Hematology/Oncology, Istanbul University Institute of Oncology, İstanbul.

Background: Chemotherapy with high dose methotrexate is the mainstay of treatment for Burkitt lymphoma (BL), especially to manage central nervous system (CNS) disease. However, methotrexate administration requires close drug level monitoring for appropriate folinic acid rescue, which might not be readily available in all centers. In this study, we assessed the long-term treatment outcomes of a modified Non-Hodgkin lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM) 90 regimen in pediatric high-risk BL without CNS involvement. Read More

View Article and Full-Text PDF
January 2021

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.

Blood Adv 2021 Aug 27. Epub 2021 Aug 27.

University of Virginia, Charlottesville, Virginia, United States.

We performed a multicenter retrospective analysis across 10 US academic medical centers (2010 - 2018) to evaluate current treatment patterns and outcomes in patients age ≥60 with classical Hodgkin lymphoma (cHL). Among 244 eligible patients, median age was 68, 63% had advanced stage (III/IV), 14% had ECOG performance status (PS) 2-4, and 12% had documented loss of ≥1 activity of daily living (ADLs). Medical comorbidities were assessed by the Cumulative Illness Rating Scale - Geriatric (CIRS-G), where n=44 (18%) had total scores ≥10. Read More

View Article and Full-Text PDF

Myocardial Metabolic Response Predicts Chemotherapy Curative Potential on Hodgkin Lymphoma: A Proof-of-Concept Study.

Biomedicines 2021 Aug 6;9(8). Epub 2021 Aug 6.

Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

Genome sharing between cancer and normal tissues might imply a similar susceptibility to chemotherapy toxicity. The present study aimed to investigate whether curative potential of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is predicted by the metabolic response of normal tissues in patients with Hodgkin lymphoma (HL).

Methods: According to current guidelines, 86 patients with advanced-stage (IIB-IVB) HL, prospectively enrolled in the HD0607 trial (NCT00795613), underwent 18 F-fluorodeoyglucose PET/CT imaging at diagnosis and, at interim, after two ABVD courses, to decide regimen maintenance or its escalation. Read More

View Article and Full-Text PDF

FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma.

Cancers (Basel) 2021 Aug 5;13(16). Epub 2021 Aug 5.

Haematology and Bone Marrow Transplantation Department, Medical University of Gdansk, 80-214 Gdansk, Poland.

In the present review, the authors report the published evidence on the use of functional imaging with FDG-PET/CT in assessing the final response to treatment in Hodgkin lymphoma. Despite a very high overall Negative Predictive Value of post-chemotherapy PET on treatment outcome ranging from 94% to 86%, according to different treatment intensity, the Positive Predicting Value proved much lower (40-25%). In the present review the Authors discuss the role of PET to guide consolidation RT over a RM after different chemotherapy regimens, both in early and in advanced-stage disease. Read More

View Article and Full-Text PDF

Impedance Spectroscopy Dynamics of Biological Neural Elements: From Memristors to Neurons and Synapses.

J Phys Chem B 2021 Sep 26;125(35):9934-9949. Epub 2021 Aug 26.

Institute of Advanced Materials (INAM), Universitat Jaume I, 12006 Castelló, Spain.

Understanding the operation of neurons and synapses is essential to reproducing biological computation. Building artificial neuromorphic networks opens the door to a new generation of faster and low-energy-consuming electronic circuits for computation. The main candidates to imitate the natural biocomputation processes, such as the generation of action potentials and spiking, are memristors. Read More

View Article and Full-Text PDF
September 2021

Alitretinoin in the treatment of cutaneous T-cell lymphoma.

Cancer Med 2021 Aug 25. Epub 2021 Aug 25.

Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany.

Introduction: In this survey, we analyzed data from patients suffering from the most common cutaneous T-cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7-year period at our outpatient department between 2015 and 2020.

Materials And Methods: We analyzed patient medical records including TNMB stage, side effects under therapy with alitretinoin, time to next treatment (TTNT), and previous photo documentation.

Results: A total of 35 patients with MF (n = 28) and SS (n = 7) were included in the study, of whom 69% were male and 31% were female. Read More

View Article and Full-Text PDF

Hepatic Hodgkin Lymphoma Presenting as Solitary Hepatic Mass Following Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder in a Patient With Rheumatoid Arthritis.

J Med Cases 2021 Feb 30;12(2):79-83. Epub 2020 Dec 30.

Department of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, 5-7-1, Koji-dai, Nishi-ku, Kobe City, 651-2273 Hyogo, Japan.

Lymphoproliferative disorders (LPDs) occur frequently in patients with rheumatoid arthritis (RA) under methotrexate treatment. Some LPDs spontaneously regressed after methotrexate discontinuation, but classic Hodgkin lymphoma (CHL)-type LPDs frequently relapse, and chemotherapy is usually required for the treatment. CHL usually spreads in contiguous lymph nodes and then infiltrates in organs at an advanced stage. Read More

View Article and Full-Text PDF
February 2021

Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis.

BMC Cancer 2021 Aug 25;21(1):955. Epub 2021 Aug 25.

Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.

Background: The improved prognosis of classic Hodgkin lymphoma (cHL) has been accompanied by elevated risks of non-cancer-specific death (non-CSD). The aim of this study was to verify the occurrence of non-CSD and its effect on rates of overall survival among adult patients with cHL.

Methods: To ensure sufficient follow-up time, we analyzed retrospective data from patients aged ≥20 years with cHL that was diagnosed between 1983 and 2005 in the Surveillance, Epidemiology, and End Results (SEER) database. Read More

View Article and Full-Text PDF

Refractory T-cell/histiocyte-rich large B-cell lymphoma in a patient with ataxia-telangiectasia caused by novel compound heterozygous variants in ATM.

Int J Hematol 2021 Aug 23. Epub 2021 Aug 23.

Department of Pediatrics, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Japan.

Ataxia-telangiectasia (A-T) is an autosomal recessive chromosomal breakage syndrome caused by mutation of the ATM (A-T mutated) gene, which encodes a protein kinase that has a major role in the cellular response to DNA damage. Approximately, 10% of A-T patients develop lymphoid malignancies. Deaths caused by extreme sensitivity to chemotherapy for malignancy have been reported, and cancer treatment in A-T is extraordinarily difficult, needing careful monitoring and individualized protocols. Read More

View Article and Full-Text PDF

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.

Leuk Lymphoma 2021 Aug 20:1-9. Epub 2021 Aug 20.

Charité - Universitätsmedizin Berlin, Medical Department, Division of Hematology, Oncology and Tumor Immunology, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Diffuse large-cell B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. About 30-40% of the patients will not be cured by standard Rituximab (R)-CHOP-like immune-chemotherapy, and many of them experience relapse and eventually succumb to their disease. Enhancing first-line efficacy in patients at higher risk, among them many elderly, is key to improve long-term outcomes. Read More

View Article and Full-Text PDF

Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.

Br J Haematol 2021 Aug 15. Epub 2021 Aug 15.

Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Frankfurt am Main, Germany.

We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET-2) tended to be more common (P = 0·1078). Read More

View Article and Full-Text PDF

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.

J Clin Oncol 2021 Aug 13:JCO2100408. Epub 2021 Aug 13.

Manchester Academic Health Science Centre, Manchester Cancer Research Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Purpose: The contemporary management of early-stage Hodgkin lymphoma (ES-HL) involves balancing the risk of late adverse effects of radiotherapy against the increased risk of relapse if radiotherapy is omitted. This study provides information on the risk of radiation-related cardiovascular disease to help personalize the delivery of radiotherapy in ES-HL.

Methods: We predicted 30-year absolute cardiovascular risk from chemotherapy and involved field radiotherapy in patients who were positron emission tomography (PET)-negative following three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy within a UK randomized trial of PET-directed therapy for ES-HL. Read More

View Article and Full-Text PDF

SERS-based DNA methylation profiling allows the differential diagnosis of malignant lymphadenopathy.

Spectrochim Acta A Mol Biomol Spectrosc 2021 Jul 21;264:120216. Epub 2021 Jul 21.

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania; Department of Hematology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

This study highlights the potential of surface-enhanced Raman scattering (SERS) to differentiate between B-cell lymphoma (BCL), T-cell lymphoma (TCL), lymph node metastasis of melanoma (Met) and control (Ctr) samples based on the specific SERS signal of DNA extracted from lymph node tissue biopsy. Differences in the methylation profiles as well as the specific interaction of malignant and non-malignant DNA with the metal nanostructure are captured in specific variations of the band at 1005 cm, attributed to 5-methylcytosine and the band at 730 cm, attributed to adenine. Thus, using the area ratio of these two SERS marker bands as input for univariate classification, an area under the curve (AUC) of 0. Read More

View Article and Full-Text PDF